The Role of Mesenchymal Stem Cells in the Induction of Cancer-Stem Cell Phenotype

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Mar 7

PMID 35251985

Authors

Yuanming Jing

Wenqing Liang

Lin Zhang

Junjun Tang

Zongliang Huang

Affiliations

Soon will be listed here.

Abstract

Cancer stem cells (CSCs) modify and form their microenvironment by recruiting and activating specific cell types such as mesenchymal stem cells (MSCs). Tumor-infiltrating MSCs help to establish a suitable tumor microenvironment for the restoration of CSCs and tumor progression. In addition, crosstalk between cancer cells and MSCs in the microenvironment induces a CSC phenotype in cancer cells. Many mechanisms are involved in crosstalk between CSCs/cancer cells and MSCs including cell-cell interaction, secretion of exosomes, and paracrine secretion of several molecules including inflammatory mediators, cytokines, and growth factors. Since this crosstalk may contribute to drug resistance, metastasis, and tumor growth, it is suggested that blockade of the crosstalk between MSCs and CSCs/cancer cells can provide a new avenue to improving the cancer therapeutic tools. In this review, we will discuss the role of MSCs in the induction of cancer stem cell phenotype and the restoration of CSCs. We also discuss targeting the crosstalk between MSCs and CSCs/cancer cells as a therapeutic strategy.

Citing Articles

Bone marrow mesenchymal stem cells enrich breast cancer stem cell population via targeting metabolic pathways.

Movahed Z, Mansouri K, Mohsen A, Matin M Med Oncol. 2025; 42(4):90.

PMID: 40045066 DOI: 10.1007/s12032-025-02632-5.

Wharton's Jelly Mesenchymal Stem Cell Conditioned Medium Ameliorates Diabetes-Induced Testicular Damage and Sperm Abnormalities by Mitigating Oxidative Stress, Apoptosis, and Inflammation.

Sargazi M, Karbalaei N, Karbalay-Doust S, Keshtgar S, Aghaei Z Stem Cells Int. 2024; 2024:7084913.

PMID: 39391856 PMC: 11466552. DOI: 10.1155/2024/7084913.

The role of mesenchymal stem cells in cancer and prospects for their use in cancer therapeutics.

Tang J, Chen Y, Wang C, Xia Y, Yu T, Tang M MedComm (2020). 2024; 5(8):e663.

PMID: 39070181 PMC: 11283587. DOI: 10.1002/mco2.663.

Promotion of stem cell-like phenotype of lung adenocarcinoma by FAM83A via stabilization of ErbB2.

Yuan Y, Hao L, Huang J, Zhao F, Ju Y, Wang J Cell Death Dis. 2024; 15(6):460.

PMID: 38942760 PMC: 11213963. DOI: 10.1038/s41419-024-06853-w.

Interconversion of Cancer Cells and Induced Pluripotent Stem Cells.

Sarker D, Xue Y, Mahmud F, Jocelyn J, Sang Q Cells. 2024; 13(2).

PMID: 38247819 PMC: 10814385. DOI: 10.3390/cells13020125.

References

Cafforio P, Viggiano L, Mannavola F, Pelle E, Caporusso C, Maiorano E . pIL6-TRAIL-engineered umbilical cord mesenchymal/stromal stem cells are highly cytotoxic for myeloma cells both in vitro and in vivo. Stem Cell Res Ther. 2017; 8(1):206. PMC: 5622499. DOI: 10.1186/s13287-017-0655-6. View

Rudnick J, Arendt L, Klebba I, Hinds J, Iyer V, Gupta P . Functional heterogeneity of breast fibroblasts is defined by a prostaglandin secretory phenotype that promotes expansion of cancer-stem like cells. PLoS One. 2011; 6(9):e24605. PMC: 3177828. DOI: 10.1371/journal.pone.0024605. View

Tsuyada A, Chow A, Wu J, Somlo G, Chu P, Loera S . CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Res. 2012; 72(11):2768-79. PMC: 3367125. DOI: 10.1158/0008-5472.CAN-11-3567. View

Timaner M, Letko-Khait N, Kotsofruk R, Benguigui M, Beyar-Katz O, Rachman-Tzemah C . Therapy-Educated Mesenchymal Stem Cells Enrich for Tumor-Initiating Cells. Cancer Res. 2018; 78(5):1253-1265. PMC: 5924870. DOI: 10.1158/0008-5472.CAN-17-1547. View

Signore M, Ricci-Vitiani L, De Maria R . Targeting apoptosis pathways in cancer stem cells. Cancer Lett. 2011; 332(2):374-82. DOI: 10.1016/j.canlet.2011.01.013. View

Zhong H, Davis A, Ouzounova M, Carrasco R, Chen C, Breen S . A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors. Cancer Res. 2016; 76(2):480-90. DOI: 10.1158/0008-5472.CAN-15-0883. View

Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H . The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 2011; 17(2):211-5. PMC: 3076220. DOI: 10.1038/nm.2284. View

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

McLean K, Gong Y, Choi Y, Deng N, Yang K, Bai S . Human ovarian carcinoma–associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production. J Clin Invest. 2011; 121(8):3206-19. PMC: 3148732. DOI: 10.1172/JCI45273. View

10.

Bruno S, Collino F, Deregibus M, Grange C, Tetta C, Camussi G . Microvesicles derived from human bone marrow mesenchymal stem cells inhibit tumor growth. Stem Cells Dev. 2012; 22(5):758-71. DOI: 10.1089/scd.2012.0304. View

11.

Gunn W, Conley A, Deininger L, Olson S, Prockop D, Gregory C . A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells. 2005; 24(4):986-91. DOI: 10.1634/stemcells.2005-0220. View

12.

Houghton J, Stoicov C, Nomura S, Rogers A, Carlson J, Li H . Gastric cancer originating from bone marrow-derived cells. Science. 2004; 306(5701):1568-71. DOI: 10.1126/science.1099513. View

13.

Kalwitz G, Endres M, Neumann K, Skriner K, Ringe J, Sezer O . Gene expression profile of adult human bone marrow-derived mesenchymal stem cells stimulated by the chemokine CXCL7. Int J Biochem Cell Biol. 2008; 41(3):649-58. DOI: 10.1016/j.biocel.2008.07.011. View

14.

Vincent T, Neve E, Johnson J, Kukalev A, Rojo F, Albanell J . A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition. Nat Cell Biol. 2009; 11(8):943-50. PMC: 3769970. DOI: 10.1038/ncb1905. View

15.

Sasportas L, Kasmieh R, Wakimoto H, Hingtgen S, van de Water J, Mohapatra G . Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci U S A. 2009; 106(12):4822-7. PMC: 2660771. DOI: 10.1073/pnas.0806647106. View

16.

Sheridan C, Kishimoto H, Fuchs R, Mehrotra S, Bhat-Nakshatri P, Turner C . CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res. 2006; 8(5):R59. PMC: 1779499. DOI: 10.1186/bcr1610. View

17.

Loebinger M, Eddaoudi A, Davies D, Janes S . Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res. 2009; 69(10):4134-42. PMC: 2699841. DOI: 10.1158/0008-5472.CAN-08-4698. View

18.

Khakoo A, Pati S, Anderson S, Reid W, Elshal M, Rovira I . Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med. 2006; 203(5):1235-47. PMC: 2121206. DOI: 10.1084/jem.20051921. View

19.

Nishimura K, Semba S, Aoyagi K, Sasaki H, Yokozaki H . Mesenchymal stem cells provide an advantageous tumor microenvironment for the restoration of cancer stem cells. Pathobiology. 2012; 79(6):290-306. DOI: 10.1159/000337296. View

20.

Ozdemir B, Pentcheva-Hoang T, Carstens J, Zheng X, Wu C, Simpson T . Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014; 25(6):719-34. PMC: 4180632. DOI: 10.1016/j.ccr.2014.04.005. View